Neuroprotective effects of cyclosporine A deserve more study

Article

Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers recently reported

Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers writing in the Journal of Glaucoma say.

The investigators stressed RGC-5 cells with 10 mM glutamate for 24 hours, sometimes adding the immunosuppressive drug (1, 3, 6, or 9 μg/mL) to the medium. They used MTS assay to study cell viability and crystal violet staining to examine cell density, and used caspase 3/7 activity and Annexin V+/PI− flow cytometry to look at apoptosis induction.

They found that RGC-5 cells incubated with 10 mM glutamate for 24 hours had a 3.1-fold decrease in overall cell viability and a 3.4-fold decrease in cell density compared with controls. Adding 9 μg/mL of CSA to 10 mM glutamate caused a 2.7-fold increase in overall cell viability and a 2.5-fold increase in cell density compared with RGC-5 cells treated only with 10 mM glutamate. Also, it significantly reduced caspase 3/7 activity by 1.3-fold and the amount of Annexin V+/PI– cells by 2.8-fold compared with RGC-5 cells incubated with 10 mM glutamate by itself.

"The neuroprotective effect of CSA dose-dependently decreased with lower concentrations," the researchers wrote.

To read the abstract of the study, click here.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.